Skip to main content

Inhibition of NLRP3 maintains microglial architecture and enhances neurological recovery after traumatic brain injury.

Cell reports. Medicine

Authors: Sergio Castro-Gomez, Luis José Medina-Centanaro, Juan Ignacio Muñoz-Manco, Ana Vieira-Saecker, Sharumathi Jeyasankar, Ida Kulińska, Tao Li, Felix D Weiss, Felix Meissner, Stephanie Schwartz, Marion Schneider, Christa E Müller, Christopher J Farady, Valentin Stein, Eicke Latz, Michael T Heneka

The NLR family pyrin domain containing protein 3 (NLRP3) inflammasome orchestrates neuroinflammation, but its role in traumatic brain injury (TBI) and the therapeutic value of pharmacological inhibition remain incompletely defined. Using Nlrp3-deficient mice and two novel orally bioavailable selective antagonists (NP3-253 and NP3-361), we investigate NLRP3-dependent mechanisms of post-traumatic neuroinflammation and functional recovery. After controlled cortical impact, NLRP3 inflammasome components, pro-inflammatory genes, and mediators are robustly upregulated during the first post-injury week. Genetic Nlrp3 deletion and post-TBI NP3-253 treatment preserve microglial architecture and reduce aggregation and redistribution of the inflammasome adaptor apoptosis-associated speck-like protein containing a CARD (ASC), while post-TBI NP3-253 and NP3-361 therapeutically accelerate neurological recovery during treatment. Longitudinal intravital imaging shows that pre-TBI NLRP3 inhibition with NP3-361 constrains post-traumatic microglial activation in vivo. These findings establish NLRP3 as a driver of post-traumatic microglial morphodynamics and support selective NLRP3 inhibition as a promising strategy to improve neurological outcomes after TBI.

Copyright © 2026. Published by Elsevier Inc.

PMID: 43063935

Participating cluster members